This invention relates generally to methods of treating post-endoscopic retrograde cholangiopancreatography pancreatitis. The method comprises sublingually or buccally administering to a patient deemed to be at risk of developing post endoscopic retrograde cholangiopancreatography pancreatitis prior to undergoing endoscopic retrograde cholangiopancreatography (ERCP), a therapeutically effective amount of a pharmaceutical composition comprising indomethacin or diclofenac or a combination thereof and a pharmaceutically acceptable carrier.

This invention relates generally to methods of treating post-endoscopic retrograde cholangiopancreatography pancreatitis. The method comprises sublingually or buccally administering to a patient deemed to be at risk of developing post endoscopic retrograde cholangiopancreatography pancreatitis prior to undergoing endoscopic retrograde cholangiopancreatography (ERCP), a therapeutically effective amount of a pharmaceutical composition comprising indomethacin or diclofenac or a combination thereof and a pharmaceutically acceptable carrier.

Disclosed herein are compounds that may be specific to PPAR and/or EGF receptors, and methods of making and using same.

Disclosed herein are compounds that may be specific to PPAR and/or EGF receptors, and methods of making and using same.

A process can be used for preparing nanoparticles containing at least one bio-resorbable polyester. The nanoparticles are in the form of a powder with a Z-Average particle size D, in the range of 3 to 450 nm, and with a polydispersity index PDI in the range of 0.01 to 0.5. The process involves emulsion-solvent extraction or emulsion-solvent evaporation, and application of ultrasonic sound.

An approach is disclosed for improving oocytes quality by increasing a follicular phase of an ovarian cycle of a patient. A target duration of the follicular phase of the patient is determined. The follicular phase is extended to improve the quality of the oocyte which improves the change of reproductive success. Non-steroidal anti-inflammatory medications is prescribed to be consumed for at least one day during the target duration by the patient. A plurality of ovary stimulating medications to be consumed only during the target duration to stimulate ovaries of the patient. Oocytes are harvested after achieving the target duration and a fertilization method is prescribed.

An approach is disclosed for improving oocytes quality by increasing a follicular phase of an ovarian cycle of a patient. A target duration of the follicular phase of the patient is determined. The follicular phase is extended to improve the quality of the oocyte which improves the change of reproductive success. Non-steroidal anti-inflammatory medications is prescribed to be consumed for at least one day during the target duration by the patient. A plurality of ovary stimulating medications to be consumed only during the target duration to stimulate ovaries of the patient. Oocytes are harvested after achieving the target duration and a fertilization method is prescribed.

A method of enhancing absorption of a therapeutic agent sublingually in a person configured to treat chronic graft-versus-host disease (cGVHD) or aphthous stomatitis. The method includes administering a therapeutically effective amount of the therapeutic agent sublingually in a person and then inserting for a predetermined treatment period a device in an oral cavity of the person, wherein the device comprising an oral retention portion that is configured to be retained in the oral cavity from the predetermined treatment period and further configured to enhance absorption of the therapeutic agent sublingually.

The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists. The invention also provides packaged pharmaceutical compositions that comprise a RARA agonist and instructions for determining if such agonist is suitable for use in treatment.

The invention provides methods that define cellular populations that are sensitive to RARA agonists and identify patient subgroups that will benefit from treatment with RARA agonists. The invention also provides packaged pharmaceutical compositions that comprise a RARA agonist and instructions for determining if such agonist is suitable for use in treatment.